Diligence memo · auto-generated · as of July 2, 2026
Maxona Pharmaceuticals, Inc.
Maxona Pharmaceuticals, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Maxona Pharmaceuticals, Inc. operates in Pharmaceuticals, based in Malvern.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Maxona Pharmaceuticals, Inc. has raised $6.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.6M on 2021-04-09.
Most recent recorded round closed around 2025-06-04.
Valuation (modeled)modeled
Provath models Maxona Pharmaceuticals, Inc. at approximately $3.1M (range $1.0M–$5.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.19× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 50 months.
Last raise 13 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 6.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 46% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.